Emerging studies suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to represent a promising step forward for body loss . Initial patient investigations have demonstrated substantial decreases in visceral fat , conceivably outperforming current obesity medications . Despite this,